Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

Abstract

Current therapy of gynecologic malignancies consists of platinum-containing chemotherapy. Resistance to therapy is associated with increased levels of interleukin (IL)-6 and prostaglandin E2 (PGE 2 ), 2 inflammatory mediators known to skew differentiation of monocytes to tumor-promoting M2 macrophages. We investigated the impact of cisplatin and carboplatin on 10 different cervical and ovarian cancer cell lines as well as on the ability of the tumor cells to affect the differentiation and function of cocultured monocytes in vitro. Treatment with cisplatin or carboplatin increased the potency of tumor cell lines to induce IL-10-producing M2 macrophages, which displayed increased levels of activated STAT3 due to tumor-produced IL-6 as well as decreased levels of activated STAT1 and STAT6 related to the PGE 2 production of tumor cells. Blockade of canonical NF-kB signaling showed that the effect of the chemotherapy was abrogated, preventing the subsequent increased production of PGE 2 and/or IL-6 by the tumor cell lines. Treatment with the COX-inhibitor indomethacin and/or the clinical monoclonal antibody against interleukin-6 receptor (IL-6R), tocilizumab, prevented M2-differentiation. Importantly, no correlation existed between the production of PGE 2 or IL-6 by cancer cells and their resistance to chemotherapy-induced cell death, indicating that other mechanisms underlie the reported chemoresistance of tumors producing these factors. Our data suggest that a chemotherapy-mediated increase in tumor-promoting M2 macrophages may form an indirect mechanism for chemoresistance. Hence, concomitant therapy with COX inhibitors and/or IL-6R antibodies might increase the clinical effect of platinum-based chemotherapy in otherwise resistant tumors. Cancer Res; 73(8); 2480-92. Ó2013 AACR.

Intratumoral HPV16-Specific T Cells Constitute a Type I–Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer

“…The phenotype and composition of dispersed tumors (and expanded TILs) were analyzed by flow (9,(12)(13)(14)(15) and time-offlight mass cytometry (CyTOF; ref. 16; Supplementary Methods).…”

Are Macrophages in Tumors Good Targets for Novel Therapeutic Approaches?

“…Dijkgraaf et al showed that blocking NF-B signaling stopped platinum chemotherapy's effect of increased IL-6 and PGE2 causing more M2 differentiation. Thus anti-IL-6 therapy is another recom-mended route for therapies (Dijkgraaf et al, 2013). Other approaches include inhibition of GM-CSF in vivo and decreased VEGF and CCL-5 as ways to reduce monocyte recruitment (Bayne et al, 2012;Elbarghati et al, 2008;Pylayeva-Gupta et al, 2012).…”

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

“…The exact mechanism behind this hematologic paraneoplastic manifestation is unclear but is most likely caused by tumor-produced hematopoietic cytokines ( e.g. GM-CSF, G-CSF, IL-6, PGE2) 13 , 29 that are known to mobilize and expand MDSC and macrophages from the bone marrow. 30 In line with our previous studies in lung and cervical cancer, 26 , 31 these myeloid cells are suppressive since in vitro depletion unleashed T cell reactivity to recall antigens and tumor antigens.…”